Group items tagged

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www.niddk.nih.gov/about-niddk/research-areas/pages/research-areas.aspx .

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding.

This Funding Opportunity Announcement (FOA) is calling for R01 grant applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications.

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that unique mechanisms contribute to the development of obesity in PWH versus people without HIV. Alterations in fat tissue biology may be central to these differences. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational research projects examining HIV infection, persistence, and comorbidities as they relate to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-15-137.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the latter years of their award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www.niddk.nih.gov/about-niddk/research-areas/pages/research-areas.aspx .

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators from backgrounds nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The R21 is intended to support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of New Investigators from backgrounds underrepresented in the biomedical and behavioral sciences. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, and K23 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Through the program, two grants of $25,000 will be awarded to graduate student researchers interested in exploring the gut microbiome, probiotics, and yogurt and how they help support and maintain human health and wellness. Topics may include the role that probiotics or yogurt play on brain function, growth and development, digestive health, weight management or heart health; and factors such as foods or nutrients that influence the gut microbiome. The grant is not designed for the investigation of disease treatment or clinical management and should focus on health and wellness, long-term health and longevity, growth and development, and/or performance.

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

The objective of the AGA Research Foundation Research Scholar Award (RSA) is to support early-career investigators working toward independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research (i.e., a minimum of 75 percent effort dedicated to the proposed project). This award will support junior faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research pertaining to celiac disease. Projects must focus on the pathophysiology, epidemiology, prevention, diagnosis, treatment or patient outcomes of celiac disease.

The objective of the AGA Research Foundation Research Scholar Award (RSA) is to support early-career investigators working toward independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research (i.e., a minimum of 75 percent effort dedicated to the proposed project). This award will support junior faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research pertaining to inflammatory bowel disease.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will host a pre-application webinar on November 9, 2020 from 3:00 PM - 4:00 PM EST (Eastern Standard Time) for the Funding Opportunity Announcement (FOA) RFA-DK-20-021 "Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)" for those interested in learning more about the FOA. The webinar is open to all prospective applicants, although participation in the webinar is not required to submit an application to RFA-DK-20-021.

This FOA will provide support for assays (and associated data analysis) of repository-held samples for studies focused on an NIDDK relevant disease.  The review of applications to this FOA will consider both access to repository-held samples and funding for assays using the samples.  These studies are expected to generate scientific discoveries on disease mechanisms, disease pathogenic processes, disease progression, or clinical responses.  Projects that make good use of the associated data from the clinical trials and studies, the original intent of the clinical study and/or trial are highly encouraged.  Exploratory studies and discovery research are encouraged especially when samples are not severely limited, the work is justified, and the goal is consistent with the original intent of the clinical research.

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets. 

NineSigma, representing a Global Biotechnology Company, invites proposals for technologies to reduce residual host Vero cell DNA for preparation of recombinant live enveloped virus vaccines.

The goal of this Funding Opportunity Announcement (FOA) is to support innovative research with human subjects to elucidate the role of gastrointestinal mucosal immunity during HIV infection, to evaluate pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection, and to conduct epidemiological studies of liver diseases and disorders in HIV patients. Proposed projects must involve individuals with HIV infection or materials or data from HIV-infected individuals.

The goal of this Funding Opportunity Announcement (FOA) is to support innovative, basic and translational, nonexempt human subjects research in two areas, gastrointestinal (GI) mucosal immunology and liver disease.